These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 28660478)

  • 21. New therapeutic targets and drugs for the treatment of chronic hepatitis B.
    Fletcher SP; Delaney WE
    Semin Liver Dis; 2013 May; 33(2):130-7. PubMed ID: 23749669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis B core protein as a therapeutic target.
    Mak LY; Wong DK; Seto WK; Lai CL; Yuen MF
    Expert Opin Ther Targets; 2017 Dec; 21(12):1153-1159. PubMed ID: 29065733
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Control and Eradication Strategies of Hepatitis B Virus.
    Shih C; Chou SF; Yang CC; Huang JY; Choijilsuren G; Jhou RS
    Trends Microbiol; 2016 Sep; 24(9):739-749. PubMed ID: 27287929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive value of intrahepatic hepatitis B virus covalently closed circular DNA and total DNA in patients with acute hepatitis B and patients with chronic hepatitis B receiving anti‑viral treatment.
    Ruan P; Zhou B; Dai X; Sun Z; Guo X; Huang J; Gong Z
    Mol Med Rep; 2014 Apr; 9(4):1135-41. PubMed ID: 24566465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Host factor-targeted hepatitis B virus therapies.
    Gehring A; Bertoletti A; Tavis JE
    Intervirology; 2014; 57(3-4):158-62. PubMed ID: 25034483
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis B cure: From discovery to regulatory approval.
    Lok AS; Zoulim F; Dusheiko G; Ghany MG
    J Hepatol; 2017 Oct; 67(4):847-861. PubMed ID: 28778687
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiviral strategies to eliminate hepatitis B virus covalently closed circular DNA (cccDNA).
    Revill P; Locarnini S
    Curr Opin Pharmacol; 2016 Oct; 30():144-150. PubMed ID: 27639371
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A role for immune modulation in achieving functional cure for chronic hepatitis B among current changes in the landscape of new treatments.
    Laupèze B; Vassilev V; Badur S
    Expert Rev Gastroenterol Hepatol; 2023; 17(11):1135-1147. PubMed ID: 37847193
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New treatments to reach functional cure: Virological approaches.
    Durantel D
    Best Pract Res Clin Gastroenterol; 2017 Jun; 31(3):329-336. PubMed ID: 28774415
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics.
    Guo JT; Guo H
    Antiviral Res; 2015 Oct; 122():91-100. PubMed ID: 26272257
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical cure strategies for hepatitis B: direct-acting antiviral drugs].
    Huang AL; Yuan ZH; Nan YM; Yang DL; Guo JT; Li WH
    Zhonghua Gan Zang Bing Za Zhi; 2020 Aug; 28(8):640-644. PubMed ID: 32911899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel approaches towards conquering hepatitis B virus infection.
    Wu GY; Chen HS
    World J Gastroenterol; 2007 Feb; 13(6):830-6. PubMed ID: 17352010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targets and future direct-acting antiviral approaches to achieve hepatitis B virus cure.
    Asselah T; Loureiro D; Boyer N; Mansouri A
    Lancet Gastroenterol Hepatol; 2019 Nov; 4(11):883-892. PubMed ID: 31609242
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unraveling the complexity of hepatitis B virus: from molecular understanding to therapeutic strategy in 50 years.
    Liu B; Wen X; Huang C; Wei Y
    Int J Biochem Cell Biol; 2013 Sep; 45(9):1987-96. PubMed ID: 23819994
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging therapeutics and relevant targets for chronic Hepatitis B.
    Song IH
    Turk J Gastroenterol; 2016 May; 27(3):210-5. PubMed ID: 27210776
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging pipeline drugs for hepatitis B infection.
    Cox N; Tillmann H
    Expert Opin Emerg Drugs; 2011 Dec; 16(4):713-29. PubMed ID: 22195605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does antiviral therapy for chronic hepatitis B reduce the risk of hepatocellular carcinoma?
    Abu-Amara M; Feld JJ
    Semin Liver Dis; 2013 May; 33(2):157-66. PubMed ID: 23749672
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New therapeutic agents for chronic hepatitis B.
    Brahmania M; Feld J; Arif A; Janssen HL
    Lancet Infect Dis; 2016 Feb; 16(2):e10-21. PubMed ID: 26795693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current status of immunomodulatory therapy in chronic hepatitis B, fifty years after discovery of the virus: Search for the "magic bullet" to kill cccDNA.
    Zhang E; Kosinska A; Lu M; Yan H; Roggendorf M
    Antiviral Res; 2015 Nov; 123():193-203. PubMed ID: 26476376
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Hepatitis C can be cured: will hepatitis B become next?].
    Chulanov VP; Zueva AP; Kostyushev DS; Brezgin SA; Volchkova EV; Maleyev VV
    Ter Arkh; 2017; 89(11):4-13. PubMed ID: 29260740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.